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Prolonged-release opioid agonist therapy:
qualitative study exploring patients’ views
of 1-week, 1-month, and 6-month
buprenorphine formulations
Joanne Neale1,2* , Charlotte N. E. Tompkins1 and John Strang1,2
Abstract
Background: Options for opioid agonist therapy (OAT) are expanding with the development of prolonged-release
(also known as extended-release) 1-week, 1-month, and 6-month formulations of buprenorphine. There is an
assumption that patients will welcome these new treatments and medication adherence will correspondingly
increase. However, there has been little research exploring patients’ views of prolonged-release buprenorphine. This
paper aims to understand which durations patients prefer and why, and to consider the findings with reference to the
development of future OAT products.
Methods: Data were generated as part of a qualitative interview study. Fieldwork was conducted in London, UK,
during 2018 (before any prolonged-release OAT formulations were licensed in Europe). Participants (n = 36)
were taking daily oral OAT (methadone or buprenorphine) or using heroin daily without OAT. They included
26 men and 10 women, aged 24–63 years. All were asked for their views on weekly, monthly, and six-monthly
duration buprenorphine. Responses were audio-recorded, transcribed, and analyzed by Iterative Categorization.
Results: Participants generally stated that having buprenorphine of different prolonged durations was positive. They
tended to believe that ‘longer’ prolonged-release formulations would be beneficial for patients who wanted to avoid
thinking about drugs and drug-using associates, wished to evade the stigma of substance use, and desired ‘normality’
and ‘recovery.’ In contrast, participants favored ‘shorter’ prolonged-release formulations for patients who are new to
OAT, worried about the safety and reliability/effectiveness of OAT, want a ‘break’ from street opioids, and need contact
with services to monitor/support them. Participants indicated that transitioning between OAT medications of different
duration would be a very individual process. Some also linked prolonged-release OAT duration to political, philosophical,
and ethical issues, such as patient coercion and mental capability.
Conclusions: Medication duration is an important but complex feature of prolonged-release buprenorphine, with
patients’ views and preferences likely to be influenced by a wide range of factors. We need further qualitative
research to explore the experiences of people who have actually used prolonged-release OAT. Meanwhile,
drug developers should continue to build flexibility and choice into OAT products to ensure that future treatment is
acceptable to patients and able to accommodate their diverse individual needs.
Keywords: Prolonged-release buprenorphine, Opioid agonist therapy, Extended-release OAT, Methadone,
Buprenorphine, Depot injections, Implants, Medication duration, Qualitative study
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Background
Opioid agonist therapy (OAT) is a well-evidenced treat-
ment for opioid use disorder that involves the prescription
of pharmaceutical opioids such as the agonist (metha-
done) and the partial agonist (buprenorphine) [1, 2]. His-
torically, OAT medications have nearly always been
prescribed for daily consumption in liquid/linctus or
tablet/film form. In recent years, however, treatment
options have started to expand with the development
and approval of a range of prolonged-release (also
known as extended-release) weekly, monthly, and
six-monthly buprenorphine products (see Table 1). In
Europe, the first prolonged-release products (weekly
and monthly buprenorphine depot injections) were li-
censed for use in November 2018 [3].
As a partial agonist, buprenorphine produces less re-
spiratory depression and weaker feelings of intoxication
than full agonists (such as heroin, diamorphine, or metha-
done) [4]. At low doses, it prevents withdrawal symptoms
and the desire to use illicit opioids. Meanwhile, high doses
do not increase intoxication [4, 5]. Buprenorphine does
not cause the cycle of highs and lows linked to opioid mis-
use and is consequently associated with a lower risk of
abuse, side effects, and overdose than full opioid agonists.
Despite this, it can precipitate withdrawal symptoms if
taken by a person with an opioid dependence who has a
full agonist in their bloodstream [2, 4–6].
Recent investment in prolonged-release buprenorphine
(implant and depot injection formulations) has been
prompted by global increases in opioid use and poor
adherence to existing short-acting opioid medications
[7–9]. Patients treated with implants and depot injec-
tions do not need to collect their medication daily
from services; a change which is expected to reduce
the treatment burden for clinicians and patients, pre-
vent medication diversion, increase treatment compli-
ance, and benefit patients living in areas where access
to medical facilities or clinics is limited [6–8]. None-
theless, there is a lack of research evidence support-
ing these assumptions. This is because studies of new
medicinal products typically focus on product
characterization, safety, and efficacy, without consider-
ing how patients might use, not use, or misuse medi-
cations once they are approved and being prescribed
within real world settings [10–14].
Responding to this information gap, we previously
undertook a focus group study (6 focus groups, 44 par-
ticipants) with current and former OAT patients who all
had a history of heroin use in order to explore their
views of different routes of OAT medication administra-
tion [14, 15]. This research found that participants
expressed both positive and negative opinions of im-
plants and depot injections. For example, they generally
welcomed being free from having to constantly attend
services and appointments—emphasizing that this would
reduce the stigma they often felt as OAT patients, enable
them to do other things, and help them begin to live
‘normal’ lives. Despite this, they worried about medica-
tion administration, effectiveness, side effects, overdos-
ing, lack of dose control, and stopping treatment once
they had started. Some additionally felt that they might
be socially isolated without their daily visit to the phar-
macy or would miss the daily ‘highs’ and ‘lows’ associ-
ated with oral methadone [14, 15].
Our analyses led us to conclude that prolonged-release
implant and depot formulations of OAT are not ‘fixed’
medications that can be administered to people to
achieve pre-determined treatment outcomes [14]. In-
stead, they are more usefully viewed as complex ‘assem-
blages’ generating uncertain outcomes. For example, an
implant or depot injection comprises a pharmaceutical
drug or drugs (e.g., buprenorphine), a dose, with a dur-
ation of action, fitted in a certain way, and manufactured
to disperse medication in a particular manner. Addition-
ally, implants and depot injections are themselves part
of wider interacting ‘assemblages’. Thus, they might gen-
erate side effects, interact with other medications, be
better understood via information sources, and be evalu-
ated by their impact on feelings of control, daily rituals
and habits, relationships, ability to travel, or employment
opportunities [14].
In this paper, we build on our prior work by taking an
in-depth look at one specific feature of prolonged-re-
lease OAT: medication duration. To this end, we con-
ducted a new qualitative interview study to explore
potential patients’ views and expectations of the three
buprenorphine dosing options that are currently avail-
able: 1 week, 1 month, and 6 months. This topic seems
particularly important to consider given that these
time periods are each associated with very different
Table 1 Licensed prolonged-release opioid agonist therapy products at 31st December 2018
Pharmaceutical drug Delivery system Duration Brand name Company Countries where licensed
(year of approval)
Buprenorphine Depot injection 1 month Sublocade™ Indivior, Richmond, VA, USA USA (2017)
Buprenorphine Depot injection 1 week and 1 month Buvidal®/
CAM2038
Camurus AB, Lund, Sweden Europe (2018) and
Australia (2018)
Buprenorphine Implant 6 months Probuphine® Titan Pharmaceuticals, Inc.,
San Francisco, CA, USA
USA (2016)
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reductions in service contact compared with daily
dosing formulations. In undertaking this analysis, our
aim is to better understand which medication dura-
tions patients prefer and why, but also to consider
our findings with reference to the development of fu-
ture OAT products.
Methods
The opportunity to conduct this work arose when one of
the companies developing prolonged-release buprenor-
phine formulations was responsive to our request for
research funding to explore prolonged-release depot bupre-
norphine, and willingness to receive prolonged-release
depot buprenorphine, from the perspective of people who
use opioids. We conducted our qualitative interview study
in London, UK, between June and October 2018 (before
any prolonged-release OAT formulations had been licensed
for use in Europe). Ethical approval was granted by a uni-
versity research ethics committee. People were eligible to
participate if they were over 18 years of age and taking pre-
scribed daily oral methadone, or prescribed daily oral
buprenorphine, or using heroin daily but not taking any
OAT. These criteria were chosen to ensure that the study
participants were broadly reflective of people who could
potentially be eligible for prolonged-release OAT, yet also
included people who were using opioids but might feel that
OAT was not appropriate for them.
In total, 36 people were interviewed. These included
26 men and 10 women, aged 24–63 years (mean
45 years). Most (n = 24) identified as White British.
Twelve were taking prescribed oral methadone, 12 were
taking prescribed oral buprenorphine, and 12 were using
heroin daily but not currently prescribed any OAT. Just
over a third (n = 16) were collecting OAT medication
from a pharmacy daily, five were collecting OAT medi-
cation 2–3 times a week, and three were collecting OAT
medication weekly. Over half (n = 21) reported that they
were currently using heroin (see Table 2 for participant
characteristics).
Participants were recruited using similar procedures
from two alcohol and other drug (AOD) treatment ser-
vices, two homeless hostels, and an AOD peer support
service. To begin, the study researcher (CT) briefed ser-
vice staff on the study aims and methods. Next, service
staff approached people whom they considered to be eli-
gible, provided them with verbal information about the
study, and asked them if they were willing for their con-
tact details to be forwarded to the research team. CT
then used the information received to contact all inter-
ested people, describe the study further, confirm eligibil-
ity, and select people with a mix of demographic
characteristics and current medication experiences to
participate in a semi-structured interview at a time that
was convenient to them.
Participants were all given a written information sheet
and asked to sign a consent form before their interview
started. The information sheet clearly stated that the
study was funded by a pharmaceutical company develop-
ing prolonged-release depot buprenorphine. However,
CT emphasized that the research team was independent
from the company. Using a topic guide, CT then ex-
plored participants’ personal circumstances, substance
use, treatment history, and views on prolonged-release
depot buprenorphine. To facilitate the discussions, she
also gave all participants basic verbal information on key
features of a product concept of a prolonged-release
buprenorphine depot injection (summarized in Table 3).
If participants expressed interest, CT additionally showed
them a prototype depot injection prefilled syringe device
that contained no active medication. The prototype
was placed on a table in a clear zip-sealed bag for
participants to view.
About half way through the interviews, participants
were asked for their views on medication duration. To this
end, they were invited to comment on why they thought
people might or might not want a weekly buprenorphine
depot medication, why they might or might not want
monthly buprenorphine depot medication, why they
Table 2 Participant characteristics





Mean (range) 45 (24–63)
Ethnicity
White/White British 24 (67%)
Black/Black British 5 (14%)
Asian/Asian British 1 (3%)
Mixed or multiple 3 (8%)
Other 3 (8%)
Current prescribed medication
Daily oral methadone 12 (33%)
Daily oral buprenorphine 12 (33%)
Daily heroin (not in treatment) 12 (33%)
Frequency of medication collection from a pharmacy
Daily 16 (44%)
2–3 times a week 5 (14%)
Weekly 3 (8%)
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might want or might not want a hypothetical bupre-
norphine depot medication that lasted 6 months,
which duration they would personally prefer, and why
they thought people might want to change between
medication durations. The hypothetical 6-month depot
medication was discussed rather than a 6-month implant
in order to keep participants focused on the duration of
the medication and not distract them by introducing a dif-
ferent delivery system.
Interviews were all conducted in private in rooms at
the five participating services and were audio recorded.
They lasted 37–100 min (median 67 min). On comple-
tion of their interview, each participant was given a £20
shopping voucher. Audio recordings were transcribed
verbatim and the transcriptions were entered into the
software programme MaxQDA v11 for coding [16]. To
this end, CT developed a coding frame based on deduct-
ive codes derived from the topic guide and inductive
codes emerging from the interview data. She next coded
all the interview data line-by-line to the coding frame.
For this paper, all data coded to the medication duration
codes were exported into Word documents for analyses
following the stages of Iterative Categorization (as out-
lined below) [17].
First, CT worked through all the Word documents
and summarized the coded data descriptively, keeping a
close record of which participants made which points.
These summaries were then passed to JN, who reviewed
them more interpretively to identify patterns and themes
in the data. Next, JN re-organized all the analyses under
four inductive headings: (i) duration choice and prefer-
ences, (ii) reasons and situations for favoring ‘longer’
prolonged-release formulations, (iii) reasons and situa-
tions for favoring ‘shorter’ prolonged-release formulations,
and (iv) reasons for transitioning between durations.
At this point, the analyses were returned to CT for
further review, team discussion, and finalization. Find-
ings are presented below and illustrated using anon-
ymized verbatim quotations.
Results
Duration choice and preferences
Whilst a few participants expressed confusion regarding
the reason why different durations had been developed,
most felt that having medications of different durations
was positive since this gave patients choice and meant
that treatment could be better tailored to meet their in-
dividual needs:
I suppose you will probably get some people that
would prefer the 7-day one, other people 28 days:
different strokes for different folks. (Participant 19,
buprenorphine, male)
Of the three medication durations, the 6-month ver-
sion generated the most divergent views. Thus, some
stated that they would ‘love it’ and it would be ‘amazing’
and the ‘best drug ever’. In contrast, others expressed
very negative views. For example, some argued that no-
body should be maintained on OAT for 6 months as the
goal must always be reduction leading to abstinence;
some voiced concerns that a 6-month formulation might
release too much medication at once, so causing people
to overdose, or have other long-term harmful side ef-
fects; and some expressed disbelief that a 6-month depot
injection could ever be effective:
I wouldn’t believe it… I don’t think there is such a
drug that can last for six months. (Participant 7,
heroin, female)
Overall, however, participants did not tend to express
a definitive preference for one duration over another; ra-
ther they identified reasons why a ‘longer’ or ‘shorter’
duration formulation would be better in specific situa-
tions or circumstances or for achieving particular
treatment-related goals.
Reasons and situations for favoring ‘longer’ prolonged-
release formulations
Participants consistently reported that a depot injection
that lasted a month, and ideally 6 months, would be
more valuable than a weekly depot injection in terms of
increasing their ability to live a ‘normal life.’ A key ex-
planation that participants gave for this was that people
using opioids would not need to attend treatment ser-
vices or pharmacies so often, and this would result in
them having more time and opportunity to do other
Table 3 Summary of the key features of the prolonged-release
buprenorphine depot injection product concept presented to
participants
Overview: provided for the treatment of opioid dependence.
Effectiveness: designed to help reduce withdrawal, craving, and patients’
use of illicit opioids.
Duration: available as weekly and monthly depot injections.
Dosage: designed to deliver a set dose every day; medication dose can
be ‘topped up’ if needed; dose reductions are only possible at the end
of the week/month; there is the option to move between weekly and
monthly injections.
Administration: under the skin (subcutaneous) injection into the patient’s
arm, buttock, stomach, or thigh by a healthcare professional.
Potential side effects: comparable to daily sublingual buprenorphine,
except for mild to moderate injection site reactions (e.g., pain, itching,
red skin, swelling, lump around the injection site).
Service attendance: no need for supervised daily dosing; may only need
to attend a clinic or pharmacy on the day of the injection, either once a
week or once a month.
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more ‘normal’ things, such as travel, work, go on holi-
day, visit friends, and be spontaneous:
[If] you’ve got something that’s going to last 28 days,
you can go on holiday, you can go and visit someone.
(Participant 18, buprenorphine, male)
Several participants also stated that a medication
which could stop cravings or withdrawal symptoms for
weeks or months would mean that people no longer
needed to commit crimes to acquire money for drugs.
Over time, participants believed that the ability to live a
more ‘normal’ life would help patients feel more positive
about themselves:
I’d be able to get up and go to work like any normal
person because… after a couple of months the
thought goes in my head, like I’m not even a drug
addict anymore. (Participant 32, heroin, male)
Relatedly, many participants explained how the longer
(1-month or 6-month) depot formulations would re-
move the stigma and embarrassment they routinely ex-
perienced as a result of having to take their medication
in a community pharmacy in front of other customers.
They also said that the longer formulations would
free them from ‘bumping into’ people who tried to
sell or give them drugs in and around pharmacies
and treatment services. Equally, they explained that
the longer formulations would alleviate the stress and
inconvenience they often experienced from having to
arrange their days around attending appointments
and pharmacies:
People haven’t got to worry about going to the
chemist daily. They haven’t got to worry about being
back at a certain time. And so, like if they did get a
job and they had to work over the time the chemist’s
shutting, they wouldn’t have to worry about, ‘Oh I’ve
got to leave work’ or ‘going to have to tell my manager’.
(Participant 28, methadone, female)
Participants sometimes added that having a medica-
tion that lasted a month or longer would provide them
with welcome respite from the physical symptoms of
withdrawal (being ‘sick’) and the constant psychological
worry that they might become ‘sick.’ In turn, they said
that this would have an important further benefit of re-
ducing the time that they spent thinking about obtaining
and using drugs:
[In] 28 days you can forget about everything about it
[heroin]… Four weeks instead of thinking [about it]
every day. (Participant 15, buprenorphine, male)
For these various reasons, participants often reported
that the 1-month and 6-month depot injections were
likely to be more appropriate for people who were ‘ser-
ious’ about ‘staying away from’ heroin than the weekly
depot injection. Some participants also noted that the
6-month depot injection would offer people more time
to really begin to address other issues underlying their
substance use, change their thinking about drugs, modify
their drug-taking behaviors and rituals, and lay the foun-
dations of ‘recovery’:
You’ve got six months to sort of like get your head
round it, work with it and recover. (Participant 18,
buprenorphine, male)
In contrast, participants stated that the weekly formu-
lation would not give people time to make any funda-
mental life changes before the medication ended, so
making it relatively easy for people to go back to using
street drugs.
Finally, several participants suggested that longer for-
mulations would be beneficial in prisons. For example,
they said that they would reduce illicit substance use,
medication diversion, and prison violence, and this
would ultimately save the prison service resources (even
though they acknowledged that some prisoners might
not like prolonged-release OAT). In addition, one par-
ticipant reported that a 6-month depot injection could
have a useful role as an ‘enforced’ community treat-
ment—providing a better alternative to a prison sentence
for people who broke the law:
If they were going out thieving, then I believe six
months [depot injection] straightaway… possibly
enforced by a judge if they’re in court… I think that
would be preferable to sending someone to jail for 12
months. (Participant 26, methadone, male)
Reasons and situations for favoring ‘shorter’ prolonged-
release formulations
Participants (particularly those currently taking pre-
scribed methadone and those using heroin but not in
treatment) repeatedly argued that the weekly depot in-
jection was best for initiating treatment. Specifically,
they reported that the shorter, weekly duration would
enable people to ‘try the medication out’ before commit-
ting to it, adding that 7 days is ‘less daunting’ when
people do not know what to expect:
I would start off with once a week to see how I
feel… to see how I go with it, because obviously it’s
new. See how your body works with it. (Participant 5,
methadone, female)
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Having a shorter initial treatment period would also,
they said, enable doctors to check that the patient was
committed to treatment, and give patients an opportun-
ity to be sure that they felt comfortable with the dose
they had been given and confident that the medication
would work for them. Indeed, participants often sug-
gested that the 1-week depot injection would be better
for people who were apprehensive or worried about
OAT, concerned that depot medication might have nega-
tive short- or long-term side effects, or anxious that lon-
ger formulations might not last as long as the drug
developers promised:
A month is like stressful getting up every day,
thinking is it going to wear off today? (Participant 16,
buprenorphine, female)
As participants further explained, people who received
the weekly depot injection would have less time to wait
for the medication to finish if they did not like the treat-
ment or if it ‘disagreed with them’. Equally, those who
were less committed to being in treatment would be able
to use heroin again after only a week (participants
noted that they could stop their treatment completely
or simply take a break from treatment and use heroin
for a period before having another buprenorphine
injection):
You can have a break off the drugs for seven days,
and when that’s over you can go on a seven-day mad
one, have a bit of heroin. (Participant 12, heroin, male)
Additionally, some participants (particularly those
already being prescribed methadone and buprenorphine
daily) suggested that the shorter weekly and monthly
depot injections would be better than a longer 6-month
option for people who were detoxing or who wanted to
be abstinent since medication doses could be tapered
down more quickly:
If it’s seven days… it would be quicker for you to get
there for the lower dose. Otherwise you’ve got to wait
the whole of the month before you can change it.
(Participant 22, methadone, female)
Participants also argued that the weekly depot injec-
tion had the advantage of enabling people to maintain
more regular contact with professionals and treatment
services. A few commented that this was particularly im-
portant for people who might struggle to remember
when their next depot injection was due. More often
participants explained that a medication cannot work in
isolation and so people need services to give them struc-
ture and support, to monitor their well-being, and to
identify and react to any difficulties they are experien-
cing before these escalate:
They might be on a monthly one [depot] and they’re
not… being seen [by professionals] often enough…
They’ve hit a depression spot or something like that
and they’re starting to try and use drugs again. You’ve
got to try and catch them… before it goes wrong, so
you can help them out. (Participant 11, methadone, male)
Lastly, one participant argued that a 6-month depot
injection was problematic as people cannot think that
far ahead and so are not capable of committing to being
in OAT for that length of time.
Reasons for transitioning between durations
Most participants recognized that it was good to have
the option of transitioning between durations in case
their circumstances altered or they changed their minds
about their treatment. Furthermore, they identified spe-
cific reasons why patients might want to transition from
shorter to longer and longer to shorter formulations. As
previously indicated, participants often argued that it
would be important to start with a weekly depot injec-
tion and then ‘work up’ to a monthly and subsequently a
6-month formulation as they became more used to, and
comfortable with, the medication:
I would stick to the weekly one before I’d go to the
monthly one. And then if everything was OK, then I
would try the monthly one. Say after you tried the
monthly one, they could come up with a 6-monthly
one, say, and then you’d only have to go once a year,
twice a year. That would be excellent. (Participant 3,
heroin, male)
Indeed, one participant explained that each increase in
duration would feel like a personal achievement, ‘demon-
strating’ that people were making progress. Nonetheless,
participants also often emphasized that once they were
stable and doing well, they would want to transition
back to shorter injection durations and lower medication
dosages as part of a reduction plan that would ultimately
allow them to achieve abstinence:
When you’ve reached your level and you’re happy and
that and you’ve decided it’s time to come off, you can
start going back to the weekly, lowering the dose.
(Participant 17, buprenorphine, male)
Despite this, a few participants maintained that they
would personally prefer to taper down their doses and
detoxify using a 6-month formulation as the longer time
period would be more comfortable and give them time
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to prepare mentally for being abstinent. This difference
of opinion was captured in participants’ assertions that
transitioning between depots of different duration would
be a very personal process as ‘everyone is different.’
Discussion
Although prolonged-release buprenorphine products are
now being developed and approved internationally, there
has been very little qualitative research exploring pa-
tients’ views and expectations of these new drug formu-
lations. As we have previously argued, depot injections
and implants are complex phenomena that comprise, in-
ter alia, different pharmaceutical drugs, doses, durations,
and ways of dispersing medication [14]. It is therefore
important to research which features of these new prod-
ucts patients like, dislike, and worry about so that we
can better understand why they might favor one product
over another, why they might refuse or not comply with
a given product, why their views and preferences might
change over time, and how future formulations can be
developed so they best meet patients’ needs. This infor-
mation will also be key to the production of best prac-
tice guidelines and/or decision tools that will help
clinicians and patients make informed choices when
confronted with an increasing array of treatment options
[for a further discussion see also 15].
In this paper, we focused on medication duration by
limiting our discussion to one pharmaceutical drug
(buprenorphine) and one delivery system (depot injec-
tion). Thus, we did not refer to implants and, for the
purposes of these analyses, we did not consider dose.
Despite this, participants still introduced variability into
the interviews because they had their own personal ex-
periences and understandings of OAT. For example,
those currently taking daily prescribed buprenorphine
appeared less likely to report that the weekly depot in-
jection was good for initiating prolonged-release OAT
(possibly because they were already used to, and com-
fortable with, with buprenorphine). Meanwhile, partic-
ipants currently using heroin and not in treatment
seemed less likely to suggest that shorter durations
were better for detoxing and abstinence (possibly be-
cause ceasing OAT was less relevant to them than to
participants currently taking prescribed methadone or
buprenorphine).
The analyses presented are, in other words, limited be-
cause we could not completely isolate medication dur-
ation from other aspects of the prolonged-release OAT
‘assemblage’ [14]. Additionally, we were asking partici-
pants to discuss forms of prolonged-release OAT not
available in the UK at the time of the interviews. What
participants think about, and expect from, a treatment
they have never actually had before may be very different
from what they might report after they have personally
experienced it. A further constraint on our analyses is
that the data derive from a qualitative study involving 36
people from just 1 UK city. Consequently, we cannot
draw any empirical generalizations or make any assump-
tions about how the findings would translate to other
countries. Further, the sample size was too small to
reliably identify any complex sub-group differences
based on variables such as gender, race, or prior OAT
experiences.
Despite these limitations, aspects of our findings are
consistent with previous research into patients’ views of
prolonged-release medication for opioid use disorder
[14, 15, 18, 19] and this supports their trustworthiness
[20]. Thus, analyses demonstrate that prolonged-release
buprenorphine is a very complex treatment and partici-
pants’ views of medication duration were influenced by
myriad factors. These included their desire to avoid be-
ing tied to services and appointments, experience less
stigma, and do more ‘normal’ things; their concerns
about treatment effectiveness, side effects, and overdos-
ing; and their worries about having less professional sup-
port, losing the intoxicating effects of agonist drugs, and
wanting to change their medication dose [14, 15, 18, 19].
Participants also generally appreciated why different du-
rations could be useful and valued having choice and
scope to move between the options. Nonetheless, a small
number of participants did not immediately see why dif-
ferent durations existed, indicating that potential pa-
tients might benefit from information explaining the
pros and cons of each.
Crucially, we found that longer duration formulations
might be more suitable for patients who want to avoid
thinking about drugs and other people who are using or
dealing drugs, patients who are keen to evade the stigma
of substance use, and patients who are seeking time and
space to enjoy some ‘normality’ and establish routines
and structure that will underpin more long-term ‘recov-
ery.’ In contrast, shorter duration formulations might be
better for patients who are new to OAT, are concerned
about the safety and reliability/effectiveness of OAT, are
interested in having a ‘break’ from using street opioids
without necessarily stopping altogether, and need con-
tact with services to monitor, provide structure, and sup-
port them. Although participants mostly thought that
patients would find it easier to reduce and detoxify by
transitioning from longer to shorter duration depot in-
jections, a few participants reported that tapering their
doses down using a 6-month prolonged-release formula-
tion would offer an easier detoxification process.
Lastly, our findings suggest some political, philosophical,
and ethical issues about prolonged-release OAT that merit
consideration. First, participants did not tend to perceive
it as a ‘maintenance’ medication; instead, they generally
assumed that the endpoint would be detoxification and
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abstinence. Indeed, some participants questioned whether
anyone should ‘ever’ be maintained on OAT. In addition,
several participants suggested that prolonged-release OAT
could be a useful criminal justice treatment, and one par-
ticipant argued that people who use opioids are incapable
of deciding to have a treatment that would last 6 months.
Participants’ focus on abstinence (rather than mainten-
ance) may have been influenced by the current emphasis
on ‘recovery’ in UK policy and practice [21–23]; therefore,
this finding might not be replicated in other countries and
policy contexts. Coerced treatment, patient choice, and
mental capability in treatment decision-making are, mean-
while, sensitive issues that have been debated in relation
to other long-acting medications such as contraception
[24, 25] and antipsychotic medications [26, 27]. It is diffi-
cult to draw any firm conclusions from the findings we re-
port here, but the relationship between medication
duration, choice, mental capability, and human rights will
almost certainly feature in future discussions about
prolonged-release OAT.
Conclusions
The data presented indicate that medication duration is
an important but complex feature of prolonged-release
buprenorphine [14]. By analyzing the views and expecta-
tions of potential patients, we have been able to under-
stand the issue of duration better. However, we now
need further qualitative research to explore the experi-
ences of people who have actually used prolonged-re-
lease OAT. This will enable us to more fully appreciate
what patients like/dislike and are willing to adhere to in
terms of duration but also in terms of other central fea-
tures of prolonged-release products, such as the
pharmaceutical drug, dose, delivery system, and dispersal
mechanism. In the meantime, we recommend that drug
developers continue to build as much flexibility and
choice as possible into OAT products. This currently
seems the best way of ensuring that tomorrow’s OAT
will be acceptable to patients and able to accommodate
their changing individual needs without undermining
their freedom or human rights.
Abbreviation
OAT: Opioid agonist therapy
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